Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis
Objective A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in ps...
Gespeichert in:
| Veröffentlicht in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2018-03, Vol.70 (3), p.345-355 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 355 |
|---|---|
| container_issue | 3 |
| container_start_page | 345 |
| container_title | Arthritis & rheumatology (Hoboken, N.J.) |
| container_volume | 70 |
| creator | Coates, Laura C. FitzGerald, Oliver Merola, Joseph F. Smolen, Josef Mens, Leonieke J. J. Bertheussen, Heidi Boehncke, Wolf‐Henning Callis Duffin, Kristina Campbell, Willemina Wit, Maarten Gladman, Dafna Gottlieb, Alice James, Jana Kavanaugh, Arthur Kristensen, Lars Erik Kvien, Tore K. Luger, Thomas McHugh, Neil Mease, Philip Nash, Peter Ogdie, Alexis Rosen, Cheryl F. Strand, Vibeke Tillett, William Veale, Douglas J. Helliwell, Philip S. |
| description | Objective
A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA).
Methods
Prior to the meeting, physicians and patients completed surveys on outcome measures. A consensus meeting of 26 rheumatologists, dermatologists, and patient research partners reviewed evidence on composite measures and potential treatment targets plus results of the surveys. The meeting consisted of plenary presentations, breakout sessions, and group discussions. International experts including members of GRAPPA and OMERACT were invited to the meeting, including the developers of all of the measures discussed. After discussions, participants voted on proposals for use, and consensus was established in a second survey.
Results
Survey results from 128 health care professionals and 139 patients were analyzed alongside a systematic literature review summarizing evidence. A weighted vote was cast for composite measures. For randomized controlled trials, the most popular measures were the PsA disease activity score (40 votes) and the GRAPPA composite index (28 votes). For clinical practice, the most popular measures were an average of scores on 3 visual analog scales (45 votes) and the disease activity in PsA score (26 votes). After discussion, there was no consensus on a composite measure. The group agreed that several composite measures could be used and that future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target, with minimal disease activity (MDA)/low disease activity as a feasible alternative. The target should include assessment of musculoskeletal disease, skin disease, and health‐related quality of life. The group recommended a treatment target of very low disease activity (VLDA) or MDA.
Conclusion
Consensus was not reached on a continuous measure of disease activity. In the interim, the group recommended several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies. |
| doi_str_mv | 10.1002/art.40391 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1971643696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2007916851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-90beb6d6ab3b630c2e6ea758b57d00aa9117781ead7e4734e6286c441271b413</originalsourceid><addsrcrecordid>eNp1ksFq3DAQhk1paUKSQ1-gCHppD5uVLFuyju7SpIWElMU9G9me3VWwra1GJuytj9BnzKmPUdlOQimJLtIw3_z_D5ooesfoOaM0XmrnzxPKFXsVHcc8Fos0punrxzdT7Cg6Q7yl4ShJBU3fRkexYopLkR5Hfy6dHfZkYx1ZA4J29Y7oviE5IiB20HtiN-Q7Wmc0Gpx6c-VNTXLnd854g8ubwde2A3INGgcHSExP1jsYOu1ta7cHsrI9Qo8D3v_6_VkjNMEvTASHJkiF5iT9lCHfjo0p1w-EMcPKdnuLxv_jMU4UDrSfchbabcFPzs8kPI3ebHSLcPZwn0TFxZdi9XVxdXP5bZVfLWqeZWyhaAWVaISueCU4rWMQoGWaValsKNVaMSZlxkA3EhLJExBxJuokYbFkVcL4SfRxlt07-3MA9GVnsIa21T3YAUumJBMJF0oE9MN_6K0dXB_ClTGlUjGRpaPgp5mqnUV0sCn3znTaHUpGy3EByrAA5bQAgX3_oDhUHTRP5ON3B2A5A3emhcPLSmW-LmbJv5Iiv5U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007916851</pqid></control><display><type>article</type><title>Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Coates, Laura C. ; FitzGerald, Oliver ; Merola, Joseph F. ; Smolen, Josef ; Mens, Leonieke J. J. ; Bertheussen, Heidi ; Boehncke, Wolf‐Henning ; Callis Duffin, Kristina ; Campbell, Willemina ; Wit, Maarten ; Gladman, Dafna ; Gottlieb, Alice ; James, Jana ; Kavanaugh, Arthur ; Kristensen, Lars Erik ; Kvien, Tore K. ; Luger, Thomas ; McHugh, Neil ; Mease, Philip ; Nash, Peter ; Ogdie, Alexis ; Rosen, Cheryl F. ; Strand, Vibeke ; Tillett, William ; Veale, Douglas J. ; Helliwell, Philip S.</creator><creatorcontrib>Coates, Laura C. ; FitzGerald, Oliver ; Merola, Joseph F. ; Smolen, Josef ; Mens, Leonieke J. J. ; Bertheussen, Heidi ; Boehncke, Wolf‐Henning ; Callis Duffin, Kristina ; Campbell, Willemina ; Wit, Maarten ; Gladman, Dafna ; Gottlieb, Alice ; James, Jana ; Kavanaugh, Arthur ; Kristensen, Lars Erik ; Kvien, Tore K. ; Luger, Thomas ; McHugh, Neil ; Mease, Philip ; Nash, Peter ; Ogdie, Alexis ; Rosen, Cheryl F. ; Strand, Vibeke ; Tillett, William ; Veale, Douglas J. ; Helliwell, Philip S.</creatorcontrib><description>Objective
A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA).
Methods
Prior to the meeting, physicians and patients completed surveys on outcome measures. A consensus meeting of 26 rheumatologists, dermatologists, and patient research partners reviewed evidence on composite measures and potential treatment targets plus results of the surveys. The meeting consisted of plenary presentations, breakout sessions, and group discussions. International experts including members of GRAPPA and OMERACT were invited to the meeting, including the developers of all of the measures discussed. After discussions, participants voted on proposals for use, and consensus was established in a second survey.
Results
Survey results from 128 health care professionals and 139 patients were analyzed alongside a systematic literature review summarizing evidence. A weighted vote was cast for composite measures. For randomized controlled trials, the most popular measures were the PsA disease activity score (40 votes) and the GRAPPA composite index (28 votes). For clinical practice, the most popular measures were an average of scores on 3 visual analog scales (45 votes) and the disease activity in PsA score (26 votes). After discussion, there was no consensus on a composite measure. The group agreed that several composite measures could be used and that future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target, with minimal disease activity (MDA)/low disease activity as a feasible alternative. The target should include assessment of musculoskeletal disease, skin disease, and health‐related quality of life. The group recommended a treatment target of very low disease activity (VLDA) or MDA.
Conclusion
Consensus was not reached on a continuous measure of disease activity. In the interim, the group recommended several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies.</description><identifier>ISSN: 2326-5191</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.40391</identifier><identifier>PMID: 29193765</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Arthritis ; Arthritis, Psoriatic - diagnosis ; Arthritis, Psoriatic - drug therapy ; Biomedical Research ; Clinical trials ; Consensus ; Disease control ; Feasibility studies ; Health care ; Humans ; Literature reviews ; Medical personnel ; Medical treatment ; Musculoskeletal diseases ; Outcome Assessment, Health Care - methods ; Pain Measurement ; Patients ; Physicians ; Polls & surveys ; Psoriasis ; Psoriatic arthritis ; Quality of Life ; Remission ; Rheumatology ; Severity of Illness Index ; Skin diseases ; Surveys and Questionnaires ; Therapeutic applications</subject><ispartof>Arthritis & rheumatology (Hoboken, N.J.), 2018-03, Vol.70 (3), p.345-355</ispartof><rights>2017, American College of Rheumatology</rights><rights>2017, American College of Rheumatology.</rights><rights>2018, American College of Rheumatology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-90beb6d6ab3b630c2e6ea758b57d00aa9117781ead7e4734e6286c441271b413</citedby><cites>FETCH-LOGICAL-c3881-90beb6d6ab3b630c2e6ea758b57d00aa9117781ead7e4734e6286c441271b413</cites><orcidid>0000-0002-4756-663X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.40391$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.40391$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29193765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coates, Laura C.</creatorcontrib><creatorcontrib>FitzGerald, Oliver</creatorcontrib><creatorcontrib>Merola, Joseph F.</creatorcontrib><creatorcontrib>Smolen, Josef</creatorcontrib><creatorcontrib>Mens, Leonieke J. J.</creatorcontrib><creatorcontrib>Bertheussen, Heidi</creatorcontrib><creatorcontrib>Boehncke, Wolf‐Henning</creatorcontrib><creatorcontrib>Callis Duffin, Kristina</creatorcontrib><creatorcontrib>Campbell, Willemina</creatorcontrib><creatorcontrib>Wit, Maarten</creatorcontrib><creatorcontrib>Gladman, Dafna</creatorcontrib><creatorcontrib>Gottlieb, Alice</creatorcontrib><creatorcontrib>James, Jana</creatorcontrib><creatorcontrib>Kavanaugh, Arthur</creatorcontrib><creatorcontrib>Kristensen, Lars Erik</creatorcontrib><creatorcontrib>Kvien, Tore K.</creatorcontrib><creatorcontrib>Luger, Thomas</creatorcontrib><creatorcontrib>McHugh, Neil</creatorcontrib><creatorcontrib>Mease, Philip</creatorcontrib><creatorcontrib>Nash, Peter</creatorcontrib><creatorcontrib>Ogdie, Alexis</creatorcontrib><creatorcontrib>Rosen, Cheryl F.</creatorcontrib><creatorcontrib>Strand, Vibeke</creatorcontrib><creatorcontrib>Tillett, William</creatorcontrib><creatorcontrib>Veale, Douglas J.</creatorcontrib><creatorcontrib>Helliwell, Philip S.</creatorcontrib><title>Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis</title><title>Arthritis & rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheumatol</addtitle><description>Objective
A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA).
Methods
Prior to the meeting, physicians and patients completed surveys on outcome measures. A consensus meeting of 26 rheumatologists, dermatologists, and patient research partners reviewed evidence on composite measures and potential treatment targets plus results of the surveys. The meeting consisted of plenary presentations, breakout sessions, and group discussions. International experts including members of GRAPPA and OMERACT were invited to the meeting, including the developers of all of the measures discussed. After discussions, participants voted on proposals for use, and consensus was established in a second survey.
Results
Survey results from 128 health care professionals and 139 patients were analyzed alongside a systematic literature review summarizing evidence. A weighted vote was cast for composite measures. For randomized controlled trials, the most popular measures were the PsA disease activity score (40 votes) and the GRAPPA composite index (28 votes). For clinical practice, the most popular measures were an average of scores on 3 visual analog scales (45 votes) and the disease activity in PsA score (26 votes). After discussion, there was no consensus on a composite measure. The group agreed that several composite measures could be used and that future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target, with minimal disease activity (MDA)/low disease activity as a feasible alternative. The target should include assessment of musculoskeletal disease, skin disease, and health‐related quality of life. The group recommended a treatment target of very low disease activity (VLDA) or MDA.
Conclusion
Consensus was not reached on a continuous measure of disease activity. In the interim, the group recommended several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies.</description><subject>Arthritis</subject><subject>Arthritis, Psoriatic - diagnosis</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Biomedical Research</subject><subject>Clinical trials</subject><subject>Consensus</subject><subject>Disease control</subject><subject>Feasibility studies</subject><subject>Health care</subject><subject>Humans</subject><subject>Literature reviews</subject><subject>Medical personnel</subject><subject>Medical treatment</subject><subject>Musculoskeletal diseases</subject><subject>Outcome Assessment, Health Care - methods</subject><subject>Pain Measurement</subject><subject>Patients</subject><subject>Physicians</subject><subject>Polls & surveys</subject><subject>Psoriasis</subject><subject>Psoriatic arthritis</subject><subject>Quality of Life</subject><subject>Remission</subject><subject>Rheumatology</subject><subject>Severity of Illness Index</subject><subject>Skin diseases</subject><subject>Surveys and Questionnaires</subject><subject>Therapeutic applications</subject><issn>2326-5191</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ksFq3DAQhk1paUKSQ1-gCHppD5uVLFuyju7SpIWElMU9G9me3VWwra1GJuytj9BnzKmPUdlOQimJLtIw3_z_D5ooesfoOaM0XmrnzxPKFXsVHcc8Fos0punrxzdT7Cg6Q7yl4ShJBU3fRkexYopLkR5Hfy6dHfZkYx1ZA4J29Y7oviE5IiB20HtiN-Q7Wmc0Gpx6c-VNTXLnd854g8ubwde2A3INGgcHSExP1jsYOu1ta7cHsrI9Qo8D3v_6_VkjNMEvTASHJkiF5iT9lCHfjo0p1w-EMcPKdnuLxv_jMU4UDrSfchbabcFPzs8kPI3ebHSLcPZwn0TFxZdi9XVxdXP5bZVfLWqeZWyhaAWVaISueCU4rWMQoGWaValsKNVaMSZlxkA3EhLJExBxJuokYbFkVcL4SfRxlt07-3MA9GVnsIa21T3YAUumJBMJF0oE9MN_6K0dXB_ClTGlUjGRpaPgp5mqnUV0sCn3znTaHUpGy3EByrAA5bQAgX3_oDhUHTRP5ON3B2A5A3emhcPLSmW-LmbJv5Iiv5U</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Coates, Laura C.</creator><creator>FitzGerald, Oliver</creator><creator>Merola, Joseph F.</creator><creator>Smolen, Josef</creator><creator>Mens, Leonieke J. J.</creator><creator>Bertheussen, Heidi</creator><creator>Boehncke, Wolf‐Henning</creator><creator>Callis Duffin, Kristina</creator><creator>Campbell, Willemina</creator><creator>Wit, Maarten</creator><creator>Gladman, Dafna</creator><creator>Gottlieb, Alice</creator><creator>James, Jana</creator><creator>Kavanaugh, Arthur</creator><creator>Kristensen, Lars Erik</creator><creator>Kvien, Tore K.</creator><creator>Luger, Thomas</creator><creator>McHugh, Neil</creator><creator>Mease, Philip</creator><creator>Nash, Peter</creator><creator>Ogdie, Alexis</creator><creator>Rosen, Cheryl F.</creator><creator>Strand, Vibeke</creator><creator>Tillett, William</creator><creator>Veale, Douglas J.</creator><creator>Helliwell, Philip S.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4756-663X</orcidid></search><sort><creationdate>201803</creationdate><title>Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis</title><author>Coates, Laura C. ; FitzGerald, Oliver ; Merola, Joseph F. ; Smolen, Josef ; Mens, Leonieke J. J. ; Bertheussen, Heidi ; Boehncke, Wolf‐Henning ; Callis Duffin, Kristina ; Campbell, Willemina ; Wit, Maarten ; Gladman, Dafna ; Gottlieb, Alice ; James, Jana ; Kavanaugh, Arthur ; Kristensen, Lars Erik ; Kvien, Tore K. ; Luger, Thomas ; McHugh, Neil ; Mease, Philip ; Nash, Peter ; Ogdie, Alexis ; Rosen, Cheryl F. ; Strand, Vibeke ; Tillett, William ; Veale, Douglas J. ; Helliwell, Philip S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-90beb6d6ab3b630c2e6ea758b57d00aa9117781ead7e4734e6286c441271b413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Arthritis</topic><topic>Arthritis, Psoriatic - diagnosis</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Biomedical Research</topic><topic>Clinical trials</topic><topic>Consensus</topic><topic>Disease control</topic><topic>Feasibility studies</topic><topic>Health care</topic><topic>Humans</topic><topic>Literature reviews</topic><topic>Medical personnel</topic><topic>Medical treatment</topic><topic>Musculoskeletal diseases</topic><topic>Outcome Assessment, Health Care - methods</topic><topic>Pain Measurement</topic><topic>Patients</topic><topic>Physicians</topic><topic>Polls & surveys</topic><topic>Psoriasis</topic><topic>Psoriatic arthritis</topic><topic>Quality of Life</topic><topic>Remission</topic><topic>Rheumatology</topic><topic>Severity of Illness Index</topic><topic>Skin diseases</topic><topic>Surveys and Questionnaires</topic><topic>Therapeutic applications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coates, Laura C.</creatorcontrib><creatorcontrib>FitzGerald, Oliver</creatorcontrib><creatorcontrib>Merola, Joseph F.</creatorcontrib><creatorcontrib>Smolen, Josef</creatorcontrib><creatorcontrib>Mens, Leonieke J. J.</creatorcontrib><creatorcontrib>Bertheussen, Heidi</creatorcontrib><creatorcontrib>Boehncke, Wolf‐Henning</creatorcontrib><creatorcontrib>Callis Duffin, Kristina</creatorcontrib><creatorcontrib>Campbell, Willemina</creatorcontrib><creatorcontrib>Wit, Maarten</creatorcontrib><creatorcontrib>Gladman, Dafna</creatorcontrib><creatorcontrib>Gottlieb, Alice</creatorcontrib><creatorcontrib>James, Jana</creatorcontrib><creatorcontrib>Kavanaugh, Arthur</creatorcontrib><creatorcontrib>Kristensen, Lars Erik</creatorcontrib><creatorcontrib>Kvien, Tore K.</creatorcontrib><creatorcontrib>Luger, Thomas</creatorcontrib><creatorcontrib>McHugh, Neil</creatorcontrib><creatorcontrib>Mease, Philip</creatorcontrib><creatorcontrib>Nash, Peter</creatorcontrib><creatorcontrib>Ogdie, Alexis</creatorcontrib><creatorcontrib>Rosen, Cheryl F.</creatorcontrib><creatorcontrib>Strand, Vibeke</creatorcontrib><creatorcontrib>Tillett, William</creatorcontrib><creatorcontrib>Veale, Douglas J.</creatorcontrib><creatorcontrib>Helliwell, Philip S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coates, Laura C.</au><au>FitzGerald, Oliver</au><au>Merola, Joseph F.</au><au>Smolen, Josef</au><au>Mens, Leonieke J. J.</au><au>Bertheussen, Heidi</au><au>Boehncke, Wolf‐Henning</au><au>Callis Duffin, Kristina</au><au>Campbell, Willemina</au><au>Wit, Maarten</au><au>Gladman, Dafna</au><au>Gottlieb, Alice</au><au>James, Jana</au><au>Kavanaugh, Arthur</au><au>Kristensen, Lars Erik</au><au>Kvien, Tore K.</au><au>Luger, Thomas</au><au>McHugh, Neil</au><au>Mease, Philip</au><au>Nash, Peter</au><au>Ogdie, Alexis</au><au>Rosen, Cheryl F.</au><au>Strand, Vibeke</au><au>Tillett, William</au><au>Veale, Douglas J.</au><au>Helliwell, Philip S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis</atitle><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheumatol</addtitle><date>2018-03</date><risdate>2018</risdate><volume>70</volume><issue>3</issue><spage>345</spage><epage>355</epage><pages>345-355</pages><issn>2326-5191</issn><eissn>2326-5205</eissn><abstract>Objective
A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA).
Methods
Prior to the meeting, physicians and patients completed surveys on outcome measures. A consensus meeting of 26 rheumatologists, dermatologists, and patient research partners reviewed evidence on composite measures and potential treatment targets plus results of the surveys. The meeting consisted of plenary presentations, breakout sessions, and group discussions. International experts including members of GRAPPA and OMERACT were invited to the meeting, including the developers of all of the measures discussed. After discussions, participants voted on proposals for use, and consensus was established in a second survey.
Results
Survey results from 128 health care professionals and 139 patients were analyzed alongside a systematic literature review summarizing evidence. A weighted vote was cast for composite measures. For randomized controlled trials, the most popular measures were the PsA disease activity score (40 votes) and the GRAPPA composite index (28 votes). For clinical practice, the most popular measures were an average of scores on 3 visual analog scales (45 votes) and the disease activity in PsA score (26 votes). After discussion, there was no consensus on a composite measure. The group agreed that several composite measures could be used and that future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target, with minimal disease activity (MDA)/low disease activity as a feasible alternative. The target should include assessment of musculoskeletal disease, skin disease, and health‐related quality of life. The group recommended a treatment target of very low disease activity (VLDA) or MDA.
Conclusion
Consensus was not reached on a continuous measure of disease activity. In the interim, the group recommended several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29193765</pmid><doi>10.1002/art.40391</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-4756-663X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2326-5191 |
| ispartof | Arthritis & rheumatology (Hoboken, N.J.), 2018-03, Vol.70 (3), p.345-355 |
| issn | 2326-5191 2326-5205 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1971643696 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Arthritis Arthritis, Psoriatic - diagnosis Arthritis, Psoriatic - drug therapy Biomedical Research Clinical trials Consensus Disease control Feasibility studies Health care Humans Literature reviews Medical personnel Medical treatment Musculoskeletal diseases Outcome Assessment, Health Care - methods Pain Measurement Patients Physicians Polls & surveys Psoriasis Psoriatic arthritis Quality of Life Remission Rheumatology Severity of Illness Index Skin diseases Surveys and Questionnaires Therapeutic applications |
| title | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T04%3A26%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Group%20for%20Research%20and%20Assessment%20of%20Psoriasis%20and%20Psoriatic%20Arthritis/Outcome%20Measures%20in%20Rheumatology%20Consensus%E2%80%90Based%20Recommendations%20and%20Research%20Agenda%20for%20Use%20of%20Composite%20Measures%20and%20Treatment%20Targets%20in%20Psoriatic%20Arthritis&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Coates,%20Laura%20C.&rft.date=2018-03&rft.volume=70&rft.issue=3&rft.spage=345&rft.epage=355&rft.pages=345-355&rft.issn=2326-5191&rft.eissn=2326-5205&rft_id=info:doi/10.1002/art.40391&rft_dat=%3Cproquest_cross%3E2007916851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2007916851&rft_id=info:pmid/29193765&rfr_iscdi=true |